Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor. The fully implantable device is replaced once a year, lasting 185 days longer than the Eversense E3 sensor and outstripping competing CGMs, which last only for 10-14 days.

• Source: Shutterstock (Shutterstock)

Senseonics Holdings and Ascensia Diabetes Care are targeting the 2024 fourth quarter for launch of the world’s first 365-day continuous glucose monitoring system, Eversense 365.

Senseonics has been working to extend the wear life of its fully implantable Eversense glucose sensors since receiving PMA approval...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Home-Testing Added To UK National Cervical Cancer Screening Program

 

NHS England will offer at-home cervical cancer self-testing kits to people who are overdue for routine screening by six months. The Department of Health and Social Care identified four HPV collection and testing combinations with highest accuracy.

ADA 2025: Tandem Becomes Abbott’s Fourth Partner In Push To Advance Dual Sensor CGM Strategy

 
• By 

Ahead of the ADA conference, Abbott announced Tandem as the fourth partner to integrate Abbott’s dual glucose-ketone sensor with automated insulin delivery. Expanded Medicare CGM coverage, FDA label expansions and new ADA guidelines position Abbott to grow its CGM footprint in a competitive market.

MHRA Opens Second AI Airlock Program For Applications

 

"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.

Stealth Mode AI Imaging Startup Faction Imaging Raises $10M

 

Faction Imaging has come out of stealth mode following six years of research and development studying medical imaging workflows in India, Japan and the US.

More from Medtech Insight

MHRA Opens Second AI Airlock Program For Applications

 

"The AI Airlock program creates a supervised testing ground where novel technologies and challenge areas can be safely investigated," said James Pound, MHRA interim executive director of innovation and compliance.

Stealth Mode AI Imaging Startup Faction Imaging Raises $10M

 

Faction Imaging has come out of stealth mode following six years of research and development studying medical imaging workflows in India, Japan and the US.

Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation

 
• By 

Remepy is exploring two potential regulatory pathways to support this strategy. The first is a combination product pathway that would formally integrate software and drug into a single therapeutic entity. The second is the FDA’s Prescription Drug Use-Related Software (PDURS) pathway.